Back to Journals » OncoTargets and Therapy » Volume 9

Prognostic value of endocan expression in cancers: evidence from meta-analysis

Authors Huang X, Chen C, Wang X, Zhang JY, Ren BH, Ma DW, Xia L, Xu XY, Xu L

Received 11 April 2016

Accepted for publication 9 September 2016

Published 13 October 2016 Volume 2016:9 Pages 6297—6304

DOI https://doi.org/10.2147/OTT.S110295

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Professor Jianmin Xu


Xing Huang,1,* Chen Chen,2,* Xin Wang,3,* Jing-yuan Zhang,1 Bin-hui Ren,3,4 Da-wei Ma,1 Lei Xia,1 Xin-yu Xu,1 Lin Xu3,4

1Department of Pathology, Nanjing Medical University Affiliated Cancer Hospital, 2Second Clinical College of Nanjing Medical University, 3Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital, 4Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, People’s Republic of China

*These authors contributed equally to this work

Abstract: Endocan is a 50 kDa dermatan sulfate proteoglycan. Numerous previous studies have indicated that endocan might be an attractive prognostic tumor biomarker. However, the results of different studies are inconsistent. We conducted a meta-analysis to explore the association between endocan expression and cancer prognosis. A systematic, comprehensive search of the PubMed, Embase, and China National Knowledge Infrastructure databases was performed. Expression of endocan and its association with overall survival were evaluated by pooled hazard ratios (HRs) and their 95% confidence intervals (CIs). In total, 15 eligible studies of 1,464 patients were finally included in this meta-analysis. A significant association was found between elevated endocan expression and poorer overall survival (pooled HR: 2.48, 95% CI: 2.12–2.90, P<0.001). In the cancer-type subgroup, significant associations were detected for gastrointestinal (HR: 2.27, 95% CI: 1.77–2.91, P<0.001) and hepatocellular (HR: 2.61, 95% CI: 1.96–3.48, P<0.001) carcinoma. Our results demonstrate that endocan could be useful to exploit as a novel prognostic biomarker for patients with cancer.

Keywords: endocan, ESM-1, biomarker, cancer, prognosis, meta-analysis
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]